Yes. Hi, Ryan, it's Linda. I'll start and then maybe turn it over to Tom. So just to kind of reiterate if you recall, when we put the convert in place, life was pretty dire, right our stock price was half of what it is today, we're in the middle of the pandemic, we're looking at really how to make sure our balance sheet was strong and defensible during a time that was - just an enormous amount of uncertainty. And Carlyle coming in and doing the preferred was a really great testament not only to their support of our business, but also to just really help us achieve the goals that we wanted to achieve at that point in time. So, I'd like really people to kind of just put all of this in context. For Carlyle, it's a great show support, but let's not forget it, it is $50 million for Carlyle, and it's $50 million for our balance sheets. So it's relatively small, and Carlyle, this is strategic right they're not looking to convert this anytime soon, it's here to support the business, and we really look at this as equity. So, compared to our dividend yield on our common stock, this is paying 7%, which is we think, actually a pretty attractive piece of equity for our balance sheet. And converting it is just not really in the cards. So I would just encourage people to think of this really as permanent equity, which you may view as expensive, but we actually view as pretty, pretty cheap. And know that this is not something that is going to dilute our current shareholders really in the foreseeable future that that we can tell. So and we're pretty conscious of that, when back when we issued this, we didn't want to dilute shareholders especially back in the Spring of 2020 and that's still our view now, there's no reason to dilute current shareholders, not when Carlyle is standing behind the business like it is. Tom, maybe you could kind of talk about our unsecured, and then just the rest of the balance sheet and how we're thinking about that?